000130935 001__ 130935
000130935 005__ 20240228143503.0
000130935 0247_ $$2doi$$a10.1055/s-0042-105292
000130935 0247_ $$2pmid$$apmid:27135271
000130935 0247_ $$2ISSN$$a0300-8630
000130935 0247_ $$2ISSN$$a1439-3824
000130935 0247_ $$2altmetric$$aaltmetric:18806773
000130935 037__ $$aDKFZ-2017-06011
000130935 041__ $$aeng
000130935 082__ $$a610
000130935 1001_ $$aWiese, M.$$b0
000130935 245__ $$aNo Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
000130935 260__ $$aStuttgart$$bThieme$$c2016
000130935 3367_ $$2DRIVER$$aarticle
000130935 3367_ $$2DataCite$$aOutput Types/Journal article
000130935 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522152818_18537
000130935 3367_ $$2BibTeX$$aARTICLE
000130935 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130935 3367_ $$00$$2EndNote$$aJournal Article
000130935 520__ $$aGlioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) belong to the most aggressive cancers in children with poor prognosis and limited therapeutic options. Therapeutic targeting of epigenetic proteins may offer new treatment options. Preclinical studies identified Enhancer of Zeste Homolog 2 (EZH2) within polycomb repressor complex 2 (PRC2) as a potential epigenetic anti-tumor target in adult GBM cells but similar inhibition studies in pediatric GBM/DIPG were still missing. Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function.The present study investigated the correlation of expression of EZH2 and other PRC2 genes (EZH1, SUZ12, EED) with overall survival of pediatric GBM patients and the cytotoxic impact of EZH2 inhibition by the novel agent Tazemetostat in pediatric GBM/DIPG cells harboring either a H3.3 mutation or a H3 wildtype.EZH2 gene expression does not correlate with survival of pedHGG patients, and EZH2 inhibition does not induce significant cytotoxicity in pedHGG cells independently of H3.3 mutations.We suggest that EZH2 inhibition might not offer an effective single agent treatment option for paedHGG patients. However, the therapeutic efficacy in combination with cytotoxic and/or other epigenetically active agents still has to be elucidated.
000130935 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130935 588__ $$aDataset connected to CrossRef, PubMed,
000130935 650_7 $$2NLM Chemicals$$aBenzamides
000130935 650_7 $$2NLM Chemicals$$aEPZ-6438
000130935 650_7 $$2NLM Chemicals$$aHistones
000130935 650_7 $$2NLM Chemicals$$aPyridones
000130935 650_7 $$0EC 2.1.1.43$$2NLM Chemicals$$aEZH2 protein, human
000130935 650_7 $$0EC 2.1.1.43$$2NLM Chemicals$$aEnhancer of Zeste Homolog 2 Protein
000130935 7001_ $$aSchill, F.$$b1
000130935 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, D.$$b2$$udkfz
000130935 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, S.$$b3$$udkfz
000130935 7001_ $$aHulleman, E.$$b4
000130935 7001_ $$aJohnsen, S. A.$$b5
000130935 7001_ $$aKramm, C. M.$$b6
000130935 773__ $$0PERI:(DE-600)2039110-9$$a10.1055/s-0042-105292$$gVol. 228, no. 3, p. 113 - 117$$n3$$p113 - 117$$tKlinische Pädiatrie$$v228$$x1439-3824$$y2016
000130935 909CO $$ooai:inrepo02.dkfz.de:130935$$pVDB
000130935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130935 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130935 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130935 9141_ $$y2016
000130935 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130935 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bKLIN PADIATR : 2015
000130935 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130935 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130935 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130935 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130935 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130935 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130935 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130935 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130935 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130935 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000130935 980__ $$ajournal
000130935 980__ $$aVDB
000130935 980__ $$aI:(DE-He78)B062-20160331
000130935 980__ $$aUNRESTRICTED